40 related articles for article (PubMed ID: 23682843)
1. Analysis of basal cell carcinomas' histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin-Goltz syndrome: A retrospective study.
Scotti B; Melotti B; Baraldi C; Comito F; Venturi F; Lambertini M; Dika E
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e339-e341. PubMed ID: 37909360
[No Abstract] [Full Text] [Related]
2. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma: Erratum.
Ophthalmic Plast Reconstr Surg; 2023 Nov-Dec 01; 39(6):655. PubMed ID: 37922051
[No Abstract] [Full Text] [Related]
3. Temporary arrest of basal cell carcinoma formation in a patient with basal cell naevus syndrome (BCNS) since treatment with a gel containing various plant extracts.
Tjeerdsma F; Jonkman MF; Spoo JR
J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):244-5. PubMed ID: 20500542
[No Abstract] [Full Text] [Related]
4. Histologic changes in basal cell carcinoma after treatment with vismodegib.
Aldabagh B; Yu J; Perkocha LA; Arron S
Dermatol Surg; 2013 Nov; 39(11):1703-5. PubMed ID: 23879864
[No Abstract] [Full Text] [Related]
5. Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome.
Booms P; Harth M; Sader R; Ghanaati S
Ann Maxillofac Surg; 2015; 5(1):14-9. PubMed ID: 26389028
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments and signaling pathway inhibitors.
Tang JY; Marghoob AA
Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S14-8. PubMed ID: 22177102
[TBL] [Abstract][Full Text] [Related]
7. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
Wolfe CM; Green WH; Cognetta AB; Hatfield HK
Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
[No Abstract] [Full Text] [Related]
8. Vismodegib in advanced basal-cell carcinoma.
Henkin RI
N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
[No Abstract] [Full Text] [Related]
9. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
Lear JT
N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
[No Abstract] [Full Text] [Related]
10. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
Kieny A; Kremer V; Scheidecker S; Lipsker D
Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
[No Abstract] [Full Text] [Related]
11. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
Chang AL; Atwood SX; Tartar DM; Oro AE
JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114
[No Abstract] [Full Text] [Related]
12. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
Ally MS; Wysong A; Tang JY; Aasi S
Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843
[No Abstract] [Full Text] [Related]
13. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
